中文 | English
Return
Total: 1658 , 1/166
Show Home Prev Next End page: GO
Author:(Du An WU)

1.Thioredoxin-interacting protein: a new potential target for diabetes and related vascular complications therapy.

Ping WU ; Guanhua DU

Acta Pharmaceutica Sinica 2015;50(12):1559-64

2.Research Advances on RGD Peptides in Diagnosis and Treatment of Neoplasms

Guocheng DU ; Chengyi WU

Chinese Journal of Bases and Clinics in General Surgery 2003;0(06):-

3.An analysis on influencing factors and preventive measures of patients with complication of lower respiratory tract infection after tracheotomy in intensive care unit

Du WU ; Jinbo PAN

Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care 2016;23(5):453-457

4.Advances in Clinical Application of Fiberoptic Ductoscopy

Guocheng DU ; Chengyi WU ;

Chinese Journal of Bases and Clinics in General Surgery 2003;0(03):-

5.Research progress of regulation effect of microRNA on tumor genes and its clinical significance

Yeping DU ; Jie WU

Cancer Research and Clinic 2013;(6):429-431

6.Diagnostic Value of Spiral CT Delay Repeated Scanning in IntracerebralSchistosomiasis(An Analysis of 49 Cases)

Wenze WU ; Xinhua DU

Journal of Practical Radiology 2001;0(07):-

7.Effects of erythropoietin on Schwann cells in vitro

Xuejian WU ; Shengyang DU

Chinese Journal of Microsurgery 2009;32(5):381-383,illust 4

8.Study progress on clinical characteristics of high myopia with primary open-angle glaucoma

Feifan DU ; Zhihong WU

Recent Advances in Ophthalmology 2017;37(7):697-700

9.STUDIES ON THE ANTIGEN LOCATION OF SCHISTOSOMA JAPONICUM, CLONORCHIS SINENSIS AND PARAGONIMUS WESTERMANI

Zhongxing WU ; Wenpin DU ;

Chinese Journal of Schistosomiasis Control 1989;0(03):-

10.Thioredoxin-interacting protein: a new potential target for diabetes and related vascular complications therapy.

Ping WU ; Guan-hua DU

Acta Pharmaceutica Sinica 2015;50(12):1559-1564

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 1658 , 1/166 Show Home Prev Next End page: GO